Executive Summary
NASA's $2.95B contract with Caltech for JPL operations signals sustained commitment to space R&D through 2028, with $2.43B already outlayed and $3.15B potential including options. Direct equity impacts are limited due to Caltech's nonprofit status, but underscores stability in NASA's FFRDC model for missions like Europa Clipper. Investors should monitor task order execution amid funding variability risks.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Tracking the trend? Catch up on the prior NASA & Space Contracts Intelligence digest from March 20, 2026.
Investment Signals (1)
- NASA JPL Funding Continuity (HIGH)▲
10-year cost-plus-fixed-fee contract with $2.95B obligated supports ongoing space science R&D, including unexercised options to $3.15B.
Risk Flags (1)
- Execution [MEDIUM RISK]▼
Extended 10-year term to 2028-09-30 exposes to funding changes; Delivery Order relies on future NASA task orders.
Opportunities (1)
- ◆
Unexercised options add $201M potential value; NASA's ongoing JPL sponsorship as FFRDC for space R&D.
Sector Themes (1)
- ◆
NASA's non-competed $2.95B award to Caltech/JPL highlights dependence on federally funded R&D centers for core missions.
Watch List (2)
- 👁
{"entity"=>"JPL Task Orders", "reason"=>"Structure ties funding to future issuances amid $2.43B outlay.", "trigger"=>"New orders or delays signaling execution risks"}
- 👁
{"entity"=>"NASA Europa Clipper Funding", "reason"=>"Key focus of JPL contract; tied to overall space science budget.", "trigger"=>"Budget adjustments or mission milestones"}
Get daily alerts with 1 investment signals, 1 risk alerts, 1 opportunities and full AI analysis of all 1 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: NASA & Space Contracts Intelligence
🇺🇸 More from United States
View all →May 27, 2026
US Pre-Market SEC Filings Roundup — May 27, 2026
US Pre-Market SEC Filings Roundup
May 27, 2026
S&P 500 Technology Sector SEC Filings — May 27, 2026
S&P 500 Technology Sector SEC Filings
May 27, 2026
Orphan Drug Approvals — May 27, 2026
Orphan Drug Approvals
May 27, 2026
Big Pharma Approvals — May 27, 2026
Big Pharma Approvals